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We present a new method based on Functional Data Analysis
(FDA) for detecting associations between one or more scalar covari-
ates and a longitudinal response, while correcting for other variables.
Our methods exploit the temporal structure of longitudinal data in
ways that are otherwise difficult with a multivariate approach. Our
procedure, from an FDA perspective, is a departure from more es-
tablished methods in two key aspects. First, the raw longitudinal
phenotypes are assembled into functional trajectories prior to analy-
sis. Second, we explore an association test that is not directly based
on principal components. We instead focus on quantifying the re-
duction in L2 variability as a means of detecting associations. Our
procedure is motivated by longitudinal genome wide association stud-
ies and, in particular, the childhood asthma management program
(CAMP) which explores the long term effects of daily asthma treat-
ments. We conduct a simulation study to better understand the ad-
vantages (and/or disadvantages) of an FDA approach compared to a
traditional multivariate one. We then apply our methodology to data
coming from CAMP. We find a potentially new association with a
SNP negatively affecting lung function. Furthermore, this SNP seems
to have an interaction effect with one of the treatments.
1. Introduction.
1.1. The childhood asthma management program. The childhood asthma
management program, CAMP, is a multi-center, longitudinal clinical trial
designed to better understand the long term impact of two common daily
asthma medications, Budesonide and Nedocromil, on children [The Child-
hood Asthma Management Program Research Group (1999, 2000)]. Sub-
jects, ages 5–12, with asthma were selected, randomly assigned a particular
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treatment (one of the two drugs or placebo) and monitored for several years.
At each clinical visit a number of measurements were taken, but the primary
one we focus on here is forced expiratory volume in one second or FEV1,
which measures the development of the lungs. The goal of the present paper
is to associate FEV1, measured longitudinally, with single nucleotide poly-
morphisms (SNPs) and to detect possible SNP by treatment interactions,
while correcting for other covariates such as age and gender. Analyzing longi-
tudinal data can be challenging and often such measurements are converted
to scalars where univariate methods can readily be applied [Tantisira et al.
(2011)]. However, since the subjects of this study are children, the develop-
ment of the child over time is also of great interest. This development can
be complicated and nonlinear as the child ages, thus, a flexible framework
to allow for such patterns is desirable. Conversely, analyzing hundreds of
thousands of SNPs requires powerful procedures which exploit any struc-
ture inherent in the data. It is reasonable to think that, while a child’s lungs
develop “nonlinearly,” their development is still relatively smooth over time,
and that major daily fluctuations in FEV1 are primarily noise independent
of the underlying development. Finally, while all children make their clini-
cal visits at approximately the same time, the spacing between visits varies
throughout the study. So a procedure which is relatively robust against dif-
ferences in temporal spacing would be vital.
1.2. Functional data analysis. Given the nature of the data and our
goals, we develop and present a framework for association testing based
on functional data analysis. Over the last two decades an abundance of
high frequency data and complex longitudinal studies have driven the de-
velopment of inferential statistical tools for samples of objects which can
Fig. 1. Plot of one subject from the CAMP study. Circles represent observed values
which are linearly interpolated by the dashed line, while the solid line is calculated using
smoothing splines.
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Fig. 2. Plots of the log(FEV1) curves for the first one hundred subjects. The left panel
displays curves obtained via smoothing splines, while the right panel displays curves which
are linearly interpolated.
be viewed as functions or trajectories. Tools falling under the umbrella of
functional data analysis (FDA) have been applied to areas such as human
growth patterns [Chen and Mu¨ller (2012), Verzelen, Tao and Mu¨ller (2012)],
gene expression [Tang and Mu¨ller (2009)], credit card transaction volumes
[Kokoszka and Reimherr (2013)], geomagnetic activity patterns [Gromenko
and Kokoszka (2013)], and neuroimaging [Reiss et al. (2011), Zipunnikov et
al. (2011)], to name only a few. The driving view in FDA is that certain data
structures can be viewed as observations from a function space. To illustrate
this point, consider Figure 1. We plot the values of log(FEV1) for one par-
ticular CAMP subject as circles, with linear interpolation indicated by a
dashed line. A nonparametric smoother based on B-splines is also plotted as
a solid line. As we can see, the B-splines have generated a curve which has
smoothed out a lot of the inherent noise in the data, giving a clearer picture
of lung development in the child.
We can obtain such a curve for every subject (and actually pool infor-
mation across children to help generate the curves). We plot the resulting
curves for the first 100 CAMP subjects (of 540 total) in Figure 2, alongside
their unsmoothed interpolated analogs. We can see that the nonparamet-
ric smoothers have decreased the noise inherent in the data, resulting in a
clear smooth trajectory for each child’s development. Our goal is then to
associate the patterns we see in the curves with SNPs and to explore SNP
by treatment interactions. However, analyzing such objects is challenging
because they are inherently infinite-dimensional objects. The approach we
outline here exploits the assumption that the functions come from a Hilbert
space by using a functional linear model to relate the functional response
variables to the univariate covariates. Define Yn(t) to be the value at time
t of the smoothed log(FEV1) curve for the nth subject. We then use the
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following linear model,
Yn(t) = α(t) +
J∑
j=1
β1,j(t)X1;j,n +
K∑
k=1
β2,k(t)X2;k,n + εn(t)(1)
for n = 1, . . . ,N , where N is the total number of subjects, and the total
number of covariates is J +K. Here the {Yn}, {X1;j,n} and {X2;k,n} are
observed. The first set of covariates {X1;j,n} will include those we wish
to correct for (gender, age, etc.), while the second set will include those
covariates we wish to test the nullity of (SNPs, treatment effects, etc.).
Therefore, the goal of this paper is test the hypothesis
H0 :β2,k(t)≡ 0 for k = 1, . . . ,K.
To test if H0 is true, we propose using the reduction in the sum of squared
norms as a testing procedure. Our approach is a kind of functional analog to
the reduction in sum of squares used in univariate ANOVA methods. This
differs from current FDA approaches which are usually based on principal
component analysis and attempt to project the infinite-dimensional problem
down to a multivariate problem. As we will note in Section 5, FDA methods
based on PCA seem to have nontrivial stability problems which become
especially evident when carrying out hundreds of thousands of tests.
While the literature on FDA and functional linear models is quite large,
we provide some key references in terms of carrying out hypothesis tests
with a functional linear model. Cardot et al. (2003) examine a PCA-based
testing procedure for a scalar response/functional covariate model which
Kokoszka et al. (2008) extends to the fully functional setting. Antoniadis
and Sapatinas (2007) examine a mixed-effects model for the modeling of
functional data and utilize a wavelet decomposition approach to carry out
inference. Zhang and Chen (2007) analyze the effect of the “smoothing first
then inference” approach to handling functional data (like the approach
considered presently) and consider an L2 normed approach for testing the
nullity of the covariates in a functional linear model. Finally, Reiss, Huang
and Mennes (2010) combine a basis expansion approach for model fitting and
a permutation testing approach for local hypothesis testing in a functional
linear model which is implemented in the R package Refund.
1.3. Alternative methodolgies. The application of FDA methods in main
stream human genetics research is present but still in its infancy. Functional
mapping methods [Ma, Cassella and Wu (2002), Wu and Lin (2006)] in ge-
netics are similar in spirit to FDA methods, but, as of yet, have not taken
advantage of the full flexibility of FDA methods. In most functional map-
ping settings very specific shapes for describing the data are instilled in the
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models with fairly simple error structures, whereas an FDA approach uti-
lizes nonparametric methods to allow for greater flexibility. More generally,
the application of FDA methods to longitudinal data is a very active area
of research; see, for example, Fan and Zhang (2000), Yao, Mu¨ller and Wang
(2005), Hall, Mu¨ller and Wang (2006), to name only a few. Typically, FDA
approaches for longitudinal data focus on estimation and obtaining principal
components which differs with our goal of powerful hypothesis testing.
More traditional longitudinal approaches model the dependence between
observations from the same subject by introducing random effects. Such
an approach typically assumes a very specific structure for the dependence
between observations, but the question of how to carry out the desired hy-
pothesis tests is not solved by introducing mixed effects. One could include
fixed effects in the form of polynomial functions over time, but given how the
children are developing, it is difficult to say which functions would be most
appropriate. Another approach would be to use time series to model the
within subject dependence. However, the time points are not evenly spaced,
the data is not stationary, and one would still have the problem of how to
carry out the hypothesis testing.
1.4. Overview. The remainder of the paper is organized as follows. In
Section 2 we present our approach based on the reduction of sum of squared
norms. We first present the single predictor case for illustrative purposes and
conclude with the general case that allows one to correct for covariates, test
the nullity of factor variables, or test the nullity of multiple covariates. In
Section 3 we explore some of the major differences between our procedure
and previous FDA approaches. In particular, we show how the difference
can be thought of as a difference in weighting schemes on the scores. This
view allows for an entire family of testing procedures by choosing different
weights. In Section 4 we present a small-scale simulation study. We show
how the smoothness of the underlying functions influences the power of our
procedure as compared to a PC-based procedure and a traditional multivari-
ate one. In Section 5 we apply our methods to a genome wide association
study on childhood asthma that has proven difficult to analyze using tra-
ditional methods. We show that there may in fact be a gene by treatment
interaction, but further validation is needed. We conclude the paper with
discussion of our results in Section 6. All asymptotic results are provided in
Appendix A, while proofs are given in Appendix B.
2. Methodology. To construct the trajectories, we first apply a subject
by subject B-splines smoother. Some type of smoothing is useful for the
CAMP data due to the inherent noise in spirometer readings. A splines-
based smoother is especially useful given the fairly smooth and nearly mono-
tonic structure of the trajectories. The smoothing parameter is chosen by
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leave-one-subject-out cross-validation, where we compare the mean of the
smoothed curves to the observed points of the left out subject. We then
form mean function, covariance function and nugget effect estimates. The
final curves are obtained by going back to each subject and kriging the
curves using the parameter estimates. Such an approach attempts to bet-
ter utilize information across subjects to help with curve construction. This
differs slightly from the smoothing methods found in the PACE package
in MATLAB (2013), as we do not utilize a PCA and we construct curves
through multiple refinements as opposed to using scatter plot smoothers.
Further details are outlined in Reimherr (2013).
We present our methods in two sections. The first considers a functional
response with one univariate quantitative covariate and provides an easier
Introduction to our methods. The second section generalizes the first so that
our methods are applicable to a wider range of settings. While we introduce
all technical notation below, precise mathematical assumptions, theorems
and proofs can be found in Appendices A and B.
Single predictor. We begin by presenting our procedure for the simpler
setting when
Yn(t) = β(t)Xn + εn(t)
for n = 1, . . . ,N , where Xn and Yn(t) are assumed to be centered. This
will provide a simpler format for introducing the more technical aspects of
FDA tools. We assume that {Xn} and {εn} are two i.i.d. sequences and
independent of each other. Without loss of generality, we will also assume
that t ∈ [0,1]. One could assume that t takes values in any closed interval,
but the results will remain the same.
The slope function β(t) we will assume to be square integrable:
‖β‖2 =
∫
β(t)2 dt <∞.
We will further assume that εn(t) is square integrable almost surely:
‖εn‖2 =
∫
εn(t)
2 dt <∞ with probability 1.
Therefore, β and εn will take values from the Hilbert space L
2[0,1] (with
probability 1) equipped with the inner product
〈x, y〉=
∫
x(t)y(t)dt.
This implies that Yn also takes values from L
2[0,1] almost surely. Through-
out, when writing ‖ · ‖ of a function, we will mean this to be the L2[0,1]
norm. We will also assume that
E[X2n]<∞ and E‖εn‖2 <∞.
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This will imply [Bosq (2000)] that εn will have a covariance function Cε(t, s)
which can be expressed as
Cε(t, s) = E[εn(t)εn(s)] =
∞∑
i=1
λivi(t)vi(s).
Note that this is simply an application of the spectral theorem. One can view
Cε(t, s) as the kernel of an integral operator acting on L
2[0,1], in which case
{λi} and {vi} will be the eigenvalues and eigenfunctions, respectively, of the
resulting operator. The moment assumptions will imply that
∞∑
i=1
λi <∞.
In functional principal component analysis, the vi are the functional prin-
cipal components, while λi will correspond to the variability explained by
the component. A functional PCA-based approach would involve choosing
a small number of vi and projecting the Yn onto them. This reduces the
infinite-dimensional problem involving Yn into a multidimensional problem
involving the scores 〈Yn, vi〉. Unfortunately, as we will note in Section 5, this
can induce stability problems in the resulting inferential tools.
We can use this assumed structure to construct a test statistic to deter-
mine if β is the zero function by examining how much the inclusion of the
covariate reduces the sum of squared norms of the Yn:
Λ =
N∑
n=1
‖Yn‖2 −
N∑
n=1
‖Yn − βˆXn‖2,
where βˆ is the pointwise least squares estimator
βˆ(t) =
∑N
n=1Yn(t)Xn∑N
n=1X
2
n
.
In this simple scenario, the procedure is equivalent to taking N‖βˆ‖2 as the
test statistic; however, for testing the nullity of multiple covariates, Λ has a
more natural generalization as we will see in the next section. By Theorem
2 in Section A, if β = 0, then as N →∞,
Λ
D→
∞∑
i=1
λiχ
2
i (1),
where χ2i (1) are i.i.d. chi-squared 1 random variables. Since the {λi} are
summable, the above will be OP (1). If β 6= 0, then
Λ =NE[X21 ]‖β‖2 +OP (1)
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as N →∞ by Theorem 2. Such a procedure does not have the stability prob-
lems inherent in PCA techniques and avoids having to choose the number of
components. A minor difficulty arises in working with the limiting distribu-
tion under the null which does not have a closed-form expression. However,
under our assumptions, the weights {λi} are summable and, in practice,
typically decrease extremely quickly. Thus, one may obtain p-values by con-
sidering the distribution of
I∑
i=1
λiχ
2
i (1)
for some large value of I . As long as I is reasonably large, the procedure
will be robust against the choice. One can estimate the {λi} by using the
eigenvalues, {λˆi}, of the empirical covariance function:
Cˆε(t, s) =
1
N − 1
∑
(Yn(t)− βˆ(t)Xn)(Yn(s)− βˆ(s)Xn).
By Theorem 3, the {λˆi} will be close to the {λi}, uniformly over i, for large
N . Thus, we can use the estimated eigenvalues to compute p-values. While
there are several methods for approximating the distribution of weighted
sums of chi-squares, we have found the method of Imhof (1961) to work
very well even for extremely small p-values which are required in genome
wide association studies. Further details and comparisons can be found in
Duchesne and Lafaye De Micheaux (2010).
Multiple predictors. In order to test the nullity of multiple predictors,
interaction terms or factor variables all while correcting for other covariates,
one requires a more general testing procedure than found in the previous
section. We now examine the larger model
Yn(t) = α(t) +
J∑
j=1
β1,j(t)X1,j;n +
K∑
k=1
β2,k(t)X2,k;n + εn(t)
= α(t) +XT1,nβ1(t) +X
T
2,nβ2(t) + εn(t).
We assume that α, {β1,j} and {β2,k} all take values in L2[0,1] and that
εn takes values in L
2[0,1] almost surely. Define the larger vector XTn =
(1,XT1,n,X
T
2,n) and assume that E[X
T
nXn] = ΣX exists and has full rank.
Assume that {Xn} and {εn} are two i.i.d. sequences and independent of
each other. As before, assume that {εn} are centered and that E‖εn‖2 <∞.
In terms of matrices, the model can be expressed as
Y(t) =X1β1(t) +X2β2(t) + ε(t),
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where we group the intercept into the first matrix of covariates. We abuse
notation slightly asX1 also refers to first observation, but, given the context,
it will always be clear what we mean. We define the corresponding least
squares estimators
βˆ1(t) = (X
T
1 X1)
−1
X
T
1 Y(t) and βˆ(t) = (X
T
X)−1XTY(t),
where
X= (X1 X2 ) .
We define the more general version of our test statistic as
Λ =
N∑
n=1
(‖Yn −XT1,nβˆ1‖2 − ‖Yn −Xnβˆ‖2).
By Theorem 4 in Appendix A, under the hypothesis that all of the β2
coordinates are zero functions, we have that, as N →∞,
Λ
D→
∞∑
i=1
λiχ
2
i (K),
where the λi are as before, but χ
2
i (K) now have K degrees of freedom
corresponding to the K covariates we are testing. Under the alternative, we
have, by Theorem 4,
Λ =N
∫
β2(t)
TΣX,2 : 1β2(t) +OP (1),
where ΣX,2 : 1 is the Schur complement
ΣX,2 : 1 =ΣX,22 −ΣX,21Σ−1X,11ΣX,12.
The matrix ΣX,2 : 1 appears since we must take into account how dependent
the second set of covariates are on the first. The empirical eigenvalues (de-
fined as before) {λˆi} can again be used for computing p-values by Theorem
5.
3. A unified framework. To better understand the difference between
our approach and an FDA approach based on principal components [Cardot
et al. (2003), Kokoszka et al. (2008)], we provide a more general testing
framework that includes both.
Consider the single predictor case. In a traditional FDA approach, one
would usually do the following. Using the observations {Yn}, form the es-
timated eigenvalues and eigenfunctions {λˆi, vˆi} and assume the {Xn} have
been standardized such that
N−1
N∑
n=1
Xi = 0 and N
−1
N∑
n=1
X2n = 1.
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Computing the eigenelements is easily done using the FDA package in R or
Matlab; see Ramsay and Silverman (2005) for more details. Then form the
test statistic as
Λ2 =
I∑
i=1
N−1(
∑N
n=1Xn〈Yn, vˆi〉)2
λˆi
.
In other words, one computes the covariance between the covariate and each
PC, then pools the results after standardizing by λˆj . We can also express
Λ2 =
I∑
i=1
N−1(
∑N
n=1Xn〈Yn, vˆi〉)2
λˆj
=
I∑
i=1
N〈βˆ, vˆi〉2
λˆi
.
When β = 0, Λ2 is asymptotically χ
2(I).
Conversely, in this simpler scenario, our Λ test statistic becomes
Λ =N‖βˆ‖2.
By Parceval’s identity, we have
N‖βˆ‖2 =N
N∑
i=1
〈βˆ, vˆi〉2.
So the difference between the two approaches in this simple case can be
thought of as a difference in weighting schemes. For the more general case,
it helps to think in terms of explained variability. Define
Λ(wN ) =N
N∑
i=1
wN (i)Rˆ
2
i ,
where Rˆ2i is the proportion of variance in the ith PC explained by the
covariates:
Rˆ2i =
∑N
n=1(〈Yn, vˆi〉 − 〈Yn −Xnβˆ, vˆi〉)2∑N
n=1〈Yn, vˆi〉2
=
〈βˆ, vˆi〉2
λˆi
.
Then Λ2 corresponds to taking
wN (i) = 11≤i≤I ,
while Λ corresponds to taking
wN (i) = λˆi.
Put in words, each scheme assigns different weights to the projections. In
the traditional case, all (standardized) projections are given equal weights,
while in our approach each (standardized) projection is weighted by the
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corresponding amount of variability it explains. Both weighting schemes
arise naturally, but there might be other meaningful choices of wN as well.
Choosing an “optimal” weighting scheme is complicated by the fact that
the PCs must be estimated and it is well known that eigenfunction estimates
can be very noisy as one moves beyond the first few PCs. Furthermore, while
Λ can be expressed using PCA for comparison purposes, it does not directly
depend on it, which avoids potential stability problems when dealing with
PCs corresponding to small eigenvalues.
4. Simulation study. We carry out a small-scale simulation study to ana-
lyze the power of our procedure as compared to other methods. We generate
data using the model
Yn(t) = β(t)Xn + εn(t).
The Xn represent a common SNP with minor allele frequency 0.5 and are
taken to be i.i.d. binomial random variables with success parameter 1/2
and trial parameter 2, centered by their mean (in this case 1). The εn are
generated as stationary, isotropic, Gaussian processes with mean zero and
covariance coming from the Ma´tern class with parameters (0,1,0,1/4,5/2),
representing mean, variance, nugget, scale and ν, respectively, where ν con-
trols the smoothness of the process. In what follows, similar results are
obtained if the εn are replaced with rougher Ma´tern processes or Brown-
ian motion (tables available upon request). Such a process will have sample
paths which are one time continuously differentiable. The covariance func-
tion can be expressed explicitly as, for t, s ∈ [0,1] and d= |t− s|,
E[εn(t)εn(s)] =C(d) =
(
1 +
√
5d
1/4
+
5d2
3/16
)
exp
(
−
√
5d
1/4
)
.
We take N = 200, use 1000 repetitions in all cases, and let M = 5,10,20,50,
where M is the number of points sampled per curve. We assume that the
points are always sampled on an even grid on the [1/M,1] interval and
the curves are reconstructed using the same approach mentioned at the
beginning of Section 2. We compare three different slope functions:
1. Linear Function: β(t) = 0.18× 2(t− 1/2)/0.5773,
2. Normal CDF: β(t) = 0.18×Φ(7.5(t− 1/2))/0.6517,
3. Sinusoidal: β(t) = 0.18×√2cos(2pit).
Notice that the functions are normalized such that the L2 norm of the
function is 0.18, which was chosen to get a clear comparison of power between
the procedures. We are especially interested in the second, as we believe its
shape to be more reflective of the types of patterns we expect to see in our
asthma data as well as human growth data in general; over the course of
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several years children grow in spurts followed by a leveling off as they get
closer to adulthood. Plots of the above functions are given in Figure 3.
The methods we compare in each scenario are as follows:
• L2: Our Method (◦),
• PC: A MANOVA performed with 3, 4, and total 5 PCs, the p-value is
then taken as the largest ( ),
• PC5: A MANOVA performed with 5 PCs ( ),
• MV: A MANOVA performed on the observed points ( ).
In parenthesis we include the plotting symbol for each procedure plotted
in Figure 4. We include both Methods PC and PC5 to illustrate the con-
sequences of having to choose the number of PCs. Method PC is common
when trying to determine if one’s results are robust against the number of
PCs chosen. Note that Methods L2, PC5 and MV are well calibrated, while
Method 2 is conservative (tables available upon request, not shown here for
brevity).
The results are summarized in Figure 4. There are a few interesting pat-
terns that become clear upon examination. The first is that the PC5 method
does quite well in all of the settings. However, the PC method does a bit
worse, as expected. This reflects the price of having to choose the number
of PCs. Our procedure’s behavior is fairly consistent across scenarios due to
the normalization of the β functions. The smoothness of the process seems
to help our method, and in the normal c.d.f. setting we seem to do quite
well, while in the sinusoidal case our method performs slightly worse. The
MV method seems to not work as well when compared to the FDA methods.
It is especially interesting to see that the multivariate approach does worse
Fig. 3. Plots of the three β functions used under the alternative hypothesis.
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Fig. 4. Power plots for 4 procedures plotted against the number of points sample per
curve (M). Method L2 is ◦, PC is , PC5 is , and MV is . The left, middle and right
panels correspond to the linear, normal c.d.f. and sinusoidal signals.
as one adds points. This is due to the high dependence of the points across
time; increasing the number of points increases the dimension, while the
high correlation between points means the overall signal does not increase
much.
We conclude this section with a closer examination of what is driving the
simulation results. Given the exposition in Section 3, we can gain insight by
looking at the R2 for each PC. That is, we project the Yn onto each PC and
in each case look at what proportion of the variability is explained by the
covariate. In Figure 5 we plot the theoretical R2 values against the PCs.
As we can see, the patterns provide a nice reflection of the power results.
For the normal setting, the R2 decreases with the PC number, while in the
sinusoidal setting one gets a peak at PC number 3 (because here β closely
matches the 3rd PC). The linear setting has a very interesting alternating
pattern (due to the PCs alternating as even/odd functions). When looking
at plots of 〈β, vj〉2 only (not shown here for brevity), one sees similar pat-
terns, but they are more subtle. It is not until those plots are scaled by the
eigenvalues that you see these very strong patterns. An important note is
Fig. 5. R2 plotted against PC number.
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that to obtain a similar looking plot empirically, that is, using empirical R2
values, one needs a rather large sample size. For N = 200, one will obtain a
very chaotic plot. It is not until N is over 1000, or better yet 10,000, that
one sees the empirical plots agreeing nicely with the theoretical ones. This is
in large part due to the difficulty in estimating eigenfunctions. Eigenvalues
are, in some sense, much easier to estimate accurately. However, the ac-
curacy of eigenfunction estimates depends greatly on what the eigenvalues
are, and, in particular, how large and spread out the values are. The smaller
an eigenvalue is, and the closer it is to another eigenvalue, the harder the
corresponding eigenfunction becomes to estimate.
5. Application. The childhood asthma management project, CAMP, is
a multi-center, longitudinal clinical trial designed to better understand the
long-term impact of several treatments for mild to moderate asthma [The
Childhood Asthma Management Program Research Group (1999, 2000)].
Subjects, ages 5–12, with asthma were selected, randomly assigned a par-
ticular treatment and monitored for several years. Our data consists of 540
Caucasian subjects monitored for 4 years, each of whom made 16 clini-
cal visits. Genome-wide SNP data and phenotype information were down-
loaded from dbGaP (http://www.ncbi.nlm.nih.gov/gap) study accession
phs000166.v2.p1. Each subject’s first three visits are 1–2 weeks apart and
occur prior to treatment; the second two visits are 2 months apart, while the
remaining 11 visits are around 4–5 months apart. While a large number of
measurements are taken, we focus on the log of forced expiratory volume in
one second (FEV1), that is, the total volume of air a subject can force out
of their lungs in one second. Each subject is given one of two treatments,
Budesonide and Nedocromil, or assigned to the Placebo group. Each treat-
ment was assigned to approximately 30% of the subjects, with the remaining
40% receiving the placebo. Trajectories were assembled using a smoothing
approach based on B-splines, the details of which can be found in Reimherr
(2013).
For each subject we have approximately six hundred and seventy thousand
SNPs genotyped after filtering out those with minor allele frequencies below
5%. We used our procedure to test for an association between FEV1 and
each SNP, while correcting for age, gender and treatment. The model is
given by (at each time point)
log(FEV1)∼ age + gender + treatment + SNP,
where we take age to be the age of the patient at the beginning of the study.
A Manhattan plot summarizing all the p-values across chromosomes is given
in Figure 6 and a QQ-plot on the log10 scale is given in Figure 7. Examining
the QQ-plot, we can see that the procedure is well calibrated, as the p-values
smaller than 0.001 fall directly on the 45 degree line, while there are also
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Fig. 6. Manhattan plot of GWAS p-values across chromosomes.
some very small p-values indicating some genetic associations. We found one
SNP with a p-value of 1.016× 10−8: rs12734254 in gene ST6GALNAC5 on
chromosome 1 (significant at the 5% significance level with a Bonferroni
correction). A plot of the estimated coefficient function is given in Figure 8.
As we can see, presence of the minor allele (frequency 41.63%) is associated
with a decrease in lung function which worsens with time. The magnitude
of the p-value remained the same for different levels of smoothing in the
Fig. 7. QQ-plot comparing GWAS p-values (y-axis, observed) to uniform distribution
(x-axis, expected) on log10 scale.
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Fig. 8. The left panel is a plot of the SNP (rs12734254) effect with pointwise confidence
intervals included as dashed lines. The right panel is a plot of the SNP by treatment
interaction with Placebo set as the baseline (in red), Budesonide is given by the solid line,
and Nedocromil as the dashed. We include grey vertical lines indicating the time of the
visits.
preprocessing step, thus, the finding is fairly robust against the initial level
of smoothing.
Next, we tested if that SNP also had an interaction effect with treatment;
we found a p-value of 0.00284. Since we used significance of the main effects
as type of screening before testing for an interaction (which resulted in one
test), we do not need to make a correction for multiple testing and, thus, the
p-value gives strong evidence that there is a SNP by treatment interaction.
In Figure 8 we plot the SNP by treatment interaction effect so that we can
better understand the nature of the interaction (with the placebo group set
as the baseline). As we can see, the interaction seems to be driven by the
difference between the Budesonide group and the Nedocromil group. The
Nedocromil group has a stronger decreasing trend, while the Budesonide
effect is actually positive. Thus, the presence of the minor allele suggests
that Budesonide might in fact have a positive impact on lung function or
that at least Budesonide can counter the effects of the deleterious SNP.
To illustrate the power gained by using the FDA approach, we compared
it to a univariate approach. If instead of using our approach we take the
difference between the endpoints and perform the same type of association
analysis (but now with a scalar response), the p-value for our SNP effect
becomes 0.002 and the p-value for the interaction test becomes 0.135. Since
this is our top SNP, we would expect the p-value for the scalar approach
to be smaller, but the drop in p-value is still quite large. More generally,
one does not need an FDA approach to exploit the temporal structure in
longitudinal data, but it does give a natural framework in which to do it.
The potential power gains made by meaningfully pooling across coordinates
should be a serious consideration in any longitudinal approach.
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Finally, we note that when using an FDA approach based on PCA we ran
into some interesting stability issues. In particular, we would on occasion see
some very large signals coming from a SNP where the rare allele was only
present in a few individuals, making the result unreliable and suspicious.
Upon closer examination, it seemed as though the PCs corresponding to
smaller eigenvalues were the culprit. This was likely due to the inherent noise
in those eigenfunctions which may have been driven by a small number of
individuals. Typically, this would not obviously be problematic, but when
carrying out a GWAS with hundreds of thousands of SNPs it is possible to
come upon a SNP present only in those individuals which are driving the
smaller PCs.
6. Discussion. We have presented a new method based on functional
data analysis for detecting genetic associations with longitudinal variables.
FDA methods allow for a flexible framework that exploits the temporal
structure of the data which can result in increased power. Two primary
advantages of our particular approach over a PCA-based test is that one
does not need to choose the number of principal components (while still
maintaining excellent power) and the interpretation of the results is not tied
to the interpretability of the shapes of the PCs, which can be especially
challenging for the nonleading eigenfunctions. Furthermore, we have found
our procedure to be substantially more stable than a PC-based method.
This became crucial when conducting hundreds of thousands of tests. We
showed how the smoothness of the trajectories and underlying parameter
functions determine the power of our procedure, as well as traditional PCA-
based methods, as compared to a multivariate approach. In particular, our
simulations reinforced the current FDA paradigm: the smoother the objects,
the greater the advantage of FDA procedures.
We applied our methodology to data coming from the childhood asthma
management study (CAMP). We showed how an association test can be
carried out which measures the effect of a SNP on a functional object, while
correcting for other covariates. We then followed that test up with an in-
teraction test. Interestingly, we found a mildly significant SNP effect with a
significant drug by SNP interaction effect. Such results are of great interest
due to the impact they can have on choosing treatment courses for patients.
A useful area for improvement would be to develop a method for esti-
mating/incorporating the interpolation error from the preprocessing step.
In high frequency settings such an error is typically very small, but in lon-
gitudinal settings where one has a relatively small number of observations
per subject, the error can be significant. Indeed, for a very small number of
points per curve (2–4) the interpolation error would be so large that classical
multivariate methods or methods based on pooled nonparametric smoothers
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might be more appropriate. Accounting for this error would hopefully help
with power and parameter estimation.
We would be excited to see more FDA methodology developed that does
not directly depend on PCA. While we have presented a method based on
L2 norms, it would be interesting to see how one could account for processes
whose covariance changes substantially over time. We mentioned the idea
of standardizing the functions to have unit variance at every time point.
However, it is still unclear how one could take into account the covariance
between time points. Indeed, it might be desirable to give less weight to
temporal regions with high dependence, since they, in some sense, carry less
information than regions with lower dependence.
We believe FDA to be a very interesting and promising method for ex-
ploiting the temporal structure in longitudinal studies. The problems facing
geneticists are quite challenging due to the sheer abundance of noise inherent
in their data. To help overcome this noise, researchers are constantly finding
new ways of exploiting information and structure. Here we have shown how
an FDA method can exploit a temporal structure to achieve better power.
Furthermore, the results are still interpretable as we are, in essence, focusing
on large scale patterns. Thus, as we saw in our application, we were able
to deliver powerful results with interpretable conclusions. While the FDA
toolbox is expanding rapidly, very little has been done which tailors FDA
techniques for genetic studies. We hope that we have taken a meaningful
step in this direction.
APPENDIX A: ASYMPTOTIC RESULTS
In this section we provide the explicit underlying assumptions and asymp-
totic results which justify the behavior of our procedure under the null and
alternative hypotheses.
Single predictor.
Assumption 1. Assume we have the following relationship:
Y (t) = β(t)X + ε(t),
where X and ε are random and take values in R and L2[0,1], respectively.
Assume that β ∈ L2[0,1] and that the following moment conditions hold:
EX = 0, E[ε(t)] = 0, EX2 <∞ and E‖ε‖2 <∞.
Finally, assume that (X1, Y1), . . . , (XN , YN ) are i.i.d. copies of (X,Y ).
Theorem 1. If Assumptions 1 holds, then
√
N(βˆ − β) D→ Z,
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where Z is a mean zero Gaussian process in L2[0,1] with covariance operator
E[ε⊗ ε]
E[X2]
.
Theorem 2. If Assumptions 1 holds and β = 0, then
Λ
D→
∞∑
i=1
λiχ
2
i (1),
where {λi} are the eigenvalues of the covariance operator of ε and {χ2i (1)}
are i.i.d. chi-squared 1 random variables. If β 6= 0 (in an L2 sense), then
Λ=NE[X2]‖β‖2 +OP (1).
Theorem 3. If Assumption 1 holds, then
Cˆε :=
1
N − 1
N∑
n=1
(Yn −Xnβˆ)⊗ (Yn −Xnβˆ) P→Cε,
where convergence occurs in the space of Hilbert–Schmidt operators and,
consequently,
sup
1≤i<∞
|λˆi − λi| ≤ ‖Cˆε −Cε‖ P→ 0,
where {λˆi} are the eigenvalues of Cˆε. If in addition E‖εn‖4 <∞, then
√
N(Cˆε −Cε) D→N (0,Γ),
where Γ =E[(ε1 ⊗ ε1 −Cε)⊗ (ε1 ⊗ ε1 −Cε)]. Consequently, one has that
sup
1≤i<∞
|λˆi − λi| ≤ ‖Cˆε −Cε‖=OP (N−1/2).
Multiple predictors.
Assumption 2. Assume we have the following relationship:
Yn(t) = α(t) +
J∑
j=1
β1,j(t)X1,j;n +
K∑
k=1
β2,k(t)X2,k;n + εn(t)
= α(t) +XT1,nβ1(t) +X
T
2,nβ2(t) + εn(t),
where J and K are fixed integers and X1,n,X2,n and ε are random and take
values in RJ , RK and L2[0,1], respectively. Assume that {β1,j} and {β2,k}
are elements of L2[0,1] and that E‖ε‖2 <∞. Let XTn = (1,XT1,n,XT2,n) and
assume that E[XTnXn] = ΣX exists and has full rank. Last, assume that
{X1, . . . ,XN} and {ε1, . . . , εN} are two i.i.d. sequences, independent of each
other, and that E[εn(t)] = 0.
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Theorem 4. If Assumptions 2 holds and β2 = 0, then
Λ
D→
∞∑
i=1
λiχ
2
i (K),
where {λi} are the eigenvalues of the covariance operator of ε and {χ2i (K)}
are i.i.d. chi-squared K random variables. If β2 6= 0, then
Λ=N
∫
β2(t)
TΣX,2 : 1β2(t) +OP (1),
where ΣX,2 : 1 is the Schur complement
ΣX,2 : 1 =ΣX,22 −ΣX,21Σ−1X,11ΣX,12.
Theorem 5. If Assumptions 2 holds, then
√
N(βˆ−β) D→N (0,Σ−1Cε),
where convergence occurs with respect to the product space (L2[0,1])N . Fur-
thermore, we have
Cˆε :=
1
N − 1− J −K
N∑
n=1
(Yn −Xnβˆ)⊗ (Yn −Xnβˆ) P→Cε,
where convergence occurs in the space of Hilbert–Schmidt operators and,
consequently,
sup
1≤i<∞
|λˆi − λi| ≤ ‖Cˆε −Cε‖ P→ 0,
where {λˆi} are the eigenvalues of Cˆε. If in addition E‖εn‖4 <∞, then
√
N(Cˆε −Cε) D→N (0,Γ),
where Γ =E[(ε1 ⊗ ε1 −Cε)⊗ (ε1 ⊗ ε1 −Cε)]. Consequently, one has
sup
1≤i<∞
|λˆi − λi| ≤ ‖Cˆε −Cε‖=OP (N−1/2).
APPENDIX B: PROOFS
Since the simpler single predictor scenario is a special case of the more
general setting, we will only prove the more general theorems.
Proof of Theorem 4. In matrix form we can express the model as
Y(t) =X1β1(t) +X2β2(t) + ε(t) =Xβ(t) + ε(t).
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We use the least squares estimators
βˆ(t) = (XTX)−1XTY(t) βˆ1(t) = (X
T
1 X1)
−1
X
T
1 Y(t).
We define our test statistic as
Λ2 =
N∑
n=1
‖Yn(t)−XT1,nβˆ1(t)‖2 −
N∑
n=1
‖Yn(t)−XTn βˆ(t)‖2.
The sum of squared residuals based on X can now be expressed as
(Y(t)−Xβˆ(t))T (Y(t)−Xβˆ(t))
= (ε(t)−X(XTX)−1XTε(t))T (ε(t)−X(XTX)−1XTε(t))
= ε(t)Tε(t)− ε(t)TX(XTX)−1Xε(t).
The residuals using only X1 can be expressed as
Y(t)−X1βˆ1(t)
=Xβ(t) + ε(t)−X1(XT1 X1)−1XT1 Y(t)
=Xβ(t) + ε(t)−X1(XT1 X1)−1XT1 Xβ(t)−X1(XT1 X1)−1XT1 ε(t)
=X2β2(t) + ε(t)−X1(XT1 X1)−1XT1 X2β2(t)−X1(XT1 X1)−1XT1 ε(t).
So the sum of squared residuals is (after expanding and combining like terms)
β2(t)
T
X
T
2 X2β2(t) + ε(t)
Tε(t)− β2(t)TXT2 X1(XT1 X1)−1XT1 X2β2(t)
− ε(t)TX1(XT1 X1)−1XT1 ε(t) + 2βT2 (t)XT2 ε(t)
− 2β2(t)TXT2 X1(XT1 X1)−1XT1 ε(t).
By examining the orders of each of the terms, one can verify that for β2 6= 0
we have
Λ2 =N
∫
β2(t)
TΣX,2 : 1β2(t)dt+OP (1).
Since ΣX has full rank, ΣX,2 : 1 is positive definite. Therefore, under the
alternative we have
Λ2→∞.
Under the null β2 = 0, the sum of squared residuals becomes
ε(t)Tε(t)− ε(t)TX1(XT1 X1)−1XT1 ε(t).
Therefore, the reduction in the sum of squared residuals by including X2 is
given by
ε(t)TX(XTX)−1XT ε(t)− ε(t)TX1(XT1 X1)−1XT1 ε(t)
= ε(t)T [X(XTX)−1XT −X1(XT1 X1)−1XT1 ]ε(t).
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Using the Hilbert space CLT, we have that
N−1/2XTε(t)
D→Z(t),
where Z(t) is a vector of Gaussian processes that can be expressed as
Z(t) = Σ
1/2
X Z
′(t),
where Z′(t) is a vector of i.i.d. Gaussian processes with covariance functions
E[εn(t)εn(s)]. Therefore, the reduction in the sum of squared residuals (by
the continuous mapping theorem and Slutsky’s lemma) is asymptotically
equal in distribution to
Z
′(t)TAZ′(t),
where
A= I−Σ1/2x
(
Σ−1x,11 0
0 0
)
Σ1/2x .
Notice that A is in fact a projection matrix with rank
rank(A) = trace(A) = (K + J)− J =K.
Therefore, we have that
Z
′(t)TAZ′(t)
D
=
K∑
k=1
Z ′k(t)
2.
This implies that the asymptotic distribution of Λ2 is now a weighted sum
of χ2(K) random variables. 
Proof of Theorem 5. We start by showing the asymptotic normality
of βˆ. Notice we can express
√
N(βˆ(t)−β(t)) =
√
N(XTX)−1XTY(t) = (N−1XTX)−1(N−1/2XTY(t)).
By the multivariate law of large numbers,
N−1XTX→ΣX .
By the CLT for Hilbert spaces,
X
T
Y
D→N (0,ΣC).
So by Slutsky’s lemma,
√
N(βˆ −β) D→N (0,Σ−1C)
as desired.
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Next, turning to the estimate of the covariance operator for the error
terms, we have
Cˆε =
1
N − 1− J −K
N∑
n=1
(Yn −Xnβˆ)⊗ (Yn −Xnβˆ)
=
1
N − 1− J −K
N∑
n=1
(εn −Xn(βˆ −β))⊗ (εn −Xn(βˆ−β)).
Examining the pieces, we have that
N∑
n=1
Xn(βˆ−β)⊗ εn =
N∑
n=1
Xn(βˆ− β)⊗ εn =OP (1)
by combining the convergence rate of βˆ and the Hilbert space CLT. Next
we have
N∑
n=1
Xn(βˆ− β)⊗Xn(βˆ− β) =OP (1)
by combining the convergence rate of βˆ and the multivariate law of large
numbers. Therefore, we can conclude
Cˆε =N
−1
N∑
n=1
εn ⊗ εn +OP (N−1).
We then immediately have that
Cε
P→Cε
by the Hilbert space law of large numbers. Notice that
‖εn ⊗ εn‖2 =
∫ ∫
εn(t)
2εn(s)
2 dt ds= ‖εn‖4.
Therefore, E‖εn‖4 <∞ implies that E‖εn ⊗ εn‖2 <∞ and by the Hilbert
space CLT we can conclude that
√
N(Cˆε −Cε)→N(0,Γ),
where
Γ = E[(εn ⊗ εn −Cε)⊗ (εn ⊗ εn −Cε)].
To obtain the final claim, we apply Corollary 4.5 on page 252 of Gohberg,
Goldberg and Kaashoek (2003), which gives
|λˆi − λi| ≤ ‖Cˆε −Cε‖. 
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